Piper Sandler raises Moderna stock price target on pipeline progress

Piper Sandler raised Moderna’s price target to $77 from $69 while keeping an Overweight rating, citing progress across the company’s Science Day pipeline, including cancer, autoimmune, and vaccine programs. Moderna also reported a unanimous FDA advisory committee vote for its seasonal flu vaccine mRNA-1010 and Europe approval for its flu/COVID combo vaccine mCOMBRIAX, with an August 5 PDUFA date ahead. The stock was cited at $66.55, and options volume surged to 121,257 contracts, led by the June 18, 2026 $65 call.

Analysis

The market is starting to price Moderna less as a one-product vaccine story and more as a platform optionality trade, but that re-rating is fragile. The near-term support comes from a visible sequence of binary catalysts that can keep implied volatility elevated, which benefits holders of calls and can force shorts to pay up for borrow and gamma. The deeper issue is that multiple shots on goal do not equal diversified cash flows; until one or two programs graduate into durable revenue, every positive read-through mainly extends the duration of the story rather than solves the earnings problem.

The second-order winner here may be not Moderna equity holders but the ecosystem around the stock: option market makers, clinical-trial service providers, and potentially peers with similar mRNA franchises that can now claim a broader category multiple. For competitors, Moderna’s progress in flu/COVID combinations raises the bar on combination convenience, but it also tightens the window for legacy vaccine incumbents to defend share without resorting to price or packaging concessions. If the upcoming catalysts disappoint, the downside can reprice quickly because the stock’s year-to-date move has left less room for incremental good news and more sensitivity to any sign that the pipeline is still pre-revenue science.

The consensus likely underestimates how much of the current valuation is now tied to event sequencing rather than fundamentals. That means the trade works best into catalyst windows and worst after them, especially if the market starts to treat positive data as already embedded. A contrarian angle is that the cleanest expression is not long equity outright, but long volatility or a call spread, because the stock can continue to oscillate on news flow even if the longer-term intrinsic value remains difficult to pin down.

Key Decisions for Investors

• Buy MRNA 1-2 month call spreads into the next catalyst window rather than outright stock; this captures event-driven upside while capping premium burn if the readout disappoints.
• For existing longs, trim 20-30% ahead of binary data and re-add only after confirmation; the stock is trading more like a catalyst basket than a fundamentally de-risked platform.
• Pair trade: long MRNA vs short a slower-moving vaccine incumbent ETF/peer basket over the next 4-8 weeks to isolate pipeline/event optionality from the broader sector multiple.
• If you want downside expression, use put spreads post-event rather than naked puts; implied volatility is likely elevated, so structure matters.
• Set a tactical profit-taking plan on any post-catalyst spike: if the market rewards a positive headline without accompanying commercial clarity, fade strength into month-end.